Molecular Targeted Therapy Global Market Report 2025

The molecular targeted therapy market size has grown strongly in recent years. It will grow from $65.78 billion in 2024 to $71.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth observed during the historic period was driven by factors such as the rising prevalence of chronic diseases, increasing demand for personalized medicine, greater use of biomarkers in drug development, wider adoption of monoclonal antibodies, and more oncology therapy approvals.

The molecular targeted therapy market size is expected to see strong growth in the next few years. It will grow to $99.4 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The projected growth in the forecast period is expected to be fueled by increased investment in cancer research, growing demand for targeted immunotherapies, expansion of clinical trial activities in precision medicine, rising use of companion diagnostics, and improved healthcare access in emerging markets. Key trends anticipated during the forecast period include advancements in genomics, innovations in drug delivery systems, increased funding for R&D, progress in molecular diagnostics, and the integration of AI technology in therapy discovery.

The rise of personalized medicine is expected to propel the growth of the molecular targeted therapy market going forward. Personalized medicine is a healthcare approach that customizes treatment and prevention based on an individual’s genetic profile, lifestyle, and environmental factors. This approach is gaining traction due to the increasing availability of genetic data, which enables treatments tailored to individual genomes for improved efficacy and reduced side effects. Personalized medicine supports molecular targeted therapy by analyzing a patient’s tumor for specific genetic mutations or biomarkers, allowing for the selection of therapies that directly target those abnormalities. This enhances treatment precision and minimizes harm to healthy tissues. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the rise of personalized medicine is driving the growth of the molecular targeted therapy market.

Major companies operating in the molecular targeted therapy market are focusing on developing advanced products such as small molecule inhibitors to improve patient outcomes in various cancers and chronic diseases. Small molecule inhibitors are tiny compounds capable of penetrating cells and inhibiting specific proteins that drive disease progression. For example, in January 2025, Amgen Inc., a US-based pharmaceutical company, introduced Lumakras (sotorasib) in combination with Vectibix (panitumumab), which received approval from the US Food and Drug Administration (FDA), a US-based government organization. This therapy is intended for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously undergone fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as confirmed by an FDA-approved test. The approval is based on the Phase 3 CodeBreaK 300 trial, which demonstrated that the combination more than doubled progression-free survival compared to the standard of care, marking the first targeted therapy to achieve such results in this chemorefractory patient group.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. Through this acquisition, Pfizer aims to bolster its oncology portfolio and expedite the development of innovative cancer therapies by leveraging Seagen’s expertise in antibody-drug conjugate (ADC) technology. Seagen Inc. is a US-based company specializing in the development of monoclonal antibody-based therapies for cancer treatment.

Major players in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

North America was the largest region in the molecular targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the molecular targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Molecular targeted therapy is an advanced form of cancer treatment that works by blocking the growth and spread of cancer cells through interference with specific molecules involved in tumor development. This therapy is tailored to the genetic and molecular profile of a patient’s tumor, aiming to increase treatment effectiveness while reducing damage to healthy cells. By focusing on cancer-specific pathways, it provides a more precise and less toxic alternative compared to traditional therapies.

The primary types of molecular targeted therapy include monoclonal antibodies, small-molecule inhibitors, gene therapy, and cell therapy. Monoclonal antibodies are specially engineered proteins that accurately target and eliminate cancer cells while sparing healthy tissue. This therapy is delivered through various methods such as oral, injectable, topical, and intravenous routes and is applied in the treatment of several cancers, including lung, breast, colorectal cancers, leukemia, and others. It is utilized by multiple end-users such as hospitals, clinics, research laboratories, and diagnostic centers.

The molecular targeted therapy market research report is one of a series of new reports that provides molecular targeted therapy market statistics, including the molecular targeted therapy industry global market size, regional shares, competitors with the molecular targeted therapy market share, detailed molecular targeted therapy market segments, market trends, opportunities, and any further data you may need to thrive in the molecular targeted therapy industry. This molecular targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The molecular targeted therapy market consists of sales of targeted cancer drugs, kinase inhibitors, hormone therapies, and companion diagnostic tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.